In summary, the COVID-19-ASM/ceramide system helps us to understand (1) the entry of SARS-CoV-2 into cells; (2) hyperinflammation and increased levels of proinflammatory cytokines, such as IL-6; (3) mortality in severe sepsis; (4) risk factors for severe disease progression, such as age, hypertension and obesity; (5) thromboembolic complications; and (6) the beneficial effects of FIASMAs during both early and later stages of COVID-19. This evidence concerns the gene IL6 and COVID-19.